Please assess the completion status of the following clinical trial:

Trial Title: Bone Marrow Aspirate Concentrate Use in Hip Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \<60 years old~* BMI of \<40 kg/m2~* Able to walk 50m unaided and not confined to a wheel chair~* Unilateral hip pain and radiographically and arthroscopically verified OA of the hip within the last 6 months (Kellgren-Lawrence grade I or II)~* HHS of less than 80~* Ability to understand the informed consent and participation instructions Attempted to use over the counter therapy without relief~* Able to participate for the entire protocol study period~* Able to follow physicians directions~Exclusion Criteria:~* Clinically significant OA in the contralateral hip~* Clinically significant pain in any other joint~* Have had intra-articular BMAC and or PRP injection within the preceding six months in the study hip~* Have had intra-articular steroid injection within the preceding three months in the study hip~* Have had previous surgical procedures on the affected hip within the preceding 6 months~* Have had a serious injury to the study hip within the previous 3 months~* Have had a serious psychological or medical condition that would interfere with their involvement~* Have had treatment with pain medications other than Tylenol and the drug remains in their system at the baseline or first study visit~* Have used of opioids other than weak opioids for OA pain more than 3 days/week within the last month~* Have used of systemic glucocorticoids (excluding inhaled steroids) within the preceding 3 months~* Treatment started with glucosamine/chondroitin sulfate or if the dosing has not been stable in the previous three months~* Has had a history of septic arthritis, skin infection or disease in the region of the injection site~* Currently using an anticoagulant excluding Aspirin 325 mg/day~* Uncontrolled diabetes~* Has any medical condition the principal investigator believes deems the patient unsuitable for the study~* Has any pathology of lumbar spine, sacroiliac (SI) joints, neuropathic or extra-articular hip pain~* Has a history of alcohol or drug abuse within the six months prior to enrolment in the study~* Has had a diagnosis of rheumatoid arthritis~* Has had a diagnosis of ankylosing spondylitis~* Has had a diagnosis of psoriatic arthritis~* Has had a diagnosis of reactive arthritis~* Has had a diagnosis of gout~* Has had a diagnosis of any connective tissue disease.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- BMAC/PRP Injection Group (Type: EXPERIMENTAL): This group will receive an injection of BMAC/PRP for treatment of OA
- Cortisone Injection Group (Type: ACTIVE_COMPARATOR): This group will receive an injection of cortisone for treatment of OA

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy